Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker OLMA
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jul 24, 2026 | Cyrus Harmon Director | OLMA Olema Oncology, Inc. | Sale | 12,500 | $11.71 | $146.4K Sale | Form 4 ↗ |
| Jul 23, 2026 | Cyrus Harmon Director | OLMA Olema Oncology, Inc. | Sale | 12,500 | $11.58 | $144.8K Sale | Form 4 ↗ |
| Mar 4, 2026 | Shawnte Mitchell CHIEF LEGAL OFFICER | OLMA Olema Oncology, Inc. | Sale | 233 | $24.69 | $5,753 Sale | Form 4 ↗ |
| Mar 4, 2026 | Shawnte Mitchell CHIEF LEGAL OFFICER | OLMA Olema Oncology, Inc. | Sale | 24,767 | $24.25 | $600.6K Sale | Form 4 ↗ |
| Mar 3, 2026 | Shawnte Mitchell CHIEF LEGAL OFFICER | OLMA Olema Oncology, Inc. | Sale | 15,000 | $23.01 | $345.1K Sale | Form 4 ↗ |
| Jan 20, 2026 | Cyrus Harmon Director | OLMA Olema Oncology, Inc. | Sale | 10,000 | $26.88 | $268.8K Sale | Form 4 ↗ |
| Jan 15, 2026 | Shane William Charles Kovacs CH. OPERATING & FINANCIAL OFF. | OLMA Olema Oncology, Inc. | Sale | 100,000 | $28.73 | $2.9M Sale | Form 4 ↗ |
| Jan 14, 2026 | Cyrus Harmon Director | OLMA Olema Oncology, Inc. | Sale | 3,489 | $29.12 | $101.6K Sale | Form 4 ↗ |
| Jan 14, 2026 | David C. Myles CH. DISCOV. & NON-CLIN DEV OFF | OLMA Olema Oncology, Inc. | Sale | 35,003 | $28.99 | $1.0M Sale | Form 4 ↗ |
| Jan 14, 2026 | David C. Myles CH. DISCOV. & NON-CLIN DEV OFF | OLMA Olema Oncology, Inc. | Sale | 14,997 | $28.60 | $428.9K Sale | Form 4 ↗ |
| Jan 13, 2026 | David C. Myles CH. DISCOV. & NON-CLIN DEV OFF | OLMA Olema Oncology, Inc. | Sale | 200 | $28.49 | $5,698 Sale | Form 4 ↗ |
| Jan 13, 2026 | David C. Myles CH. DISCOV. & NON-CLIN DEV OFF | OLMA Olema Oncology, Inc. | Sale | 49,800 | $27.60 | $1.4M Sale | Form 4 ↗ |
| Jan 13, 2026 | Shane William Charles Kovacs CH. OPERATING & FINANCIAL OFF. | OLMA Olema Oncology, Inc. | Sale | 3,822 | $28.01 | $107.1K Sale | Form 4 ↗ |
| Jan 12, 2026 | David C. Myles CH. DISCOV. & NON-CLIN DEV OFF | OLMA Olema Oncology, Inc. | Sale | 10,000 | $28.34 | $283.4K Sale | Form 4 ↗ |
| Dec 23, 2025 | Naseem Zojwalla Chief Medical Officer | OLMA Olema Oncology, Inc. | Sale | 99,509 | $27.66 | $2.8M Sale | Form 4 ↗ |
| Dec 22, 2025 | Naseem Zojwalla Chief Medical Officer | OLMA Olema Oncology, Inc. | Sale | 100,000 | $28.04 | $2.8M Sale | Form 4 ↗ |
| Dec 22, 2025 | Cyrus Harmon Director | OLMA Olema Oncology, Inc. | Sale | 2,881 | $28.53 | $82.2K Sale | Form 4 ↗ |
| Dec 19, 2025 | Naseem Zojwalla Chief Medical Officer | OLMA Olema Oncology, Inc. | Sale | 12,921 | $28.93 | $373.8K Sale | Form 4 ↗ |
| Dec 19, 2025 | Naseem Zojwalla Chief Medical Officer | OLMA Olema Oncology, Inc. | Sale | 57,079 | $28.03 | $1.6M Sale | Form 4 ↗ |
| Dec 19, 2025 | David C. Myles CH. DISCOV. & NON-CLIN DEV OFF | OLMA Olema Oncology, Inc. | Sale | 6,046 | $31.39 | $189.8K Sale | Form 4 ↗ |
| Dec 19, 2025 | David C. Myles CH. DISCOV. & NON-CLIN DEV OFF | OLMA Olema Oncology, Inc. | Sale | 43,729 | $30.40 | $1.3M Sale | Form 4 ↗ |
| Dec 19, 2025 | David C. Myles CH. DISCOV. & NON-CLIN DEV OFF | OLMA Olema Oncology, Inc. | Sale | 1,225 | $28.08 | $34.4K Sale | Form 4 ↗ |
| Dec 19, 2025 | Ian T. Clark Director | OLMA Olema Oncology, Inc. | Sale | 41,840 | $30.48 | $1.3M Sale | Form 4 ↗ |
| Dec 19, 2025 | Ian T. Clark Director | OLMA Olema Oncology, Inc. | Sale | 193,056 | $29.71 | $5.7M Sale | Form 4 ↗ |
| Dec 19, 2025 | Ian T. Clark Director | OLMA Olema Oncology, Inc. | Sale | 29,904 | $28.83 | $862.1K Sale | Form 4 ↗ |
| Sep 18, 2025 | Cyrus Harmon Director | OLMA Olema Oncology, Inc. | Sale | 3,086 | $8.32 | $25.7K Sale | Form 4 ↗ |
| Sep 18, 2025 | Cyrus Harmon Director | OLMA Olema Oncology, Inc. | Sale | 10,000 | $8.33 | $83.3K Sale | Form 4 ↗ |
| Sep 16, 2025 | Cyrus Harmon Director | OLMA Olema Oncology, Inc. | Sale | 1,914 | $8.08 | $15.5K Sale | Form 4 ↗ |
| Sep 16, 2025 | Cyrus Harmon Director | OLMA Olema Oncology, Inc. | Sale | 10,000 | $8.04 | $80.4K Sale | Form 4 ↗ |
| Jan 8, 2025 | Bain Capital Life Sciences Investors, LLC 10% owner | OLMA Olema Oncology, Inc. | Buy | 300,000 | $5.76 | $1.7M Buy | Form 4 ↗ |
| Dec 13, 2024 | Graham G. Walmsley Director | OLMA Olema Oncology, Inc. | Buy | 700,761 | $6.75 | $4.7M Buy | Form 4/A ↗ |
| Dec 13, 2024 | Graham G. Walmsley Director | OLMA Olema Oncology, Inc. | Sale | 700,761 | $6.75 | $4.7M Sale | Form 4/A ↗ |
| Dec 11, 2024 | Cyrus Harmon Director | OLMA Olema Oncology, Inc. | Sale | 179 | $9.39 | $1,681 Sale | Form 4 ↗ |
| Dec 11, 2024 | Cyrus Harmon Director | OLMA Olema Oncology, Inc. | Sale | 7,958 | $8.66 | $68.9K Sale | Form 4 ↗ |
| Dec 11, 2024 | David C. Myles CH. DISCOV. & NON-CLIN DEV OFF | OLMA Olema Oncology, Inc. | Sale | 300 | $9.39 | $2,817 Sale | Form 4 ↗ |
| Dec 11, 2024 | David C. Myles CH. DISCOV. & NON-CLIN DEV OFF | OLMA Olema Oncology, Inc. | Sale | 13,314 | $8.66 | $115.3K Sale | Form 4 ↗ |
| Dec 11, 2024 | Naseem Zojwalla CHIEF MEDICAL OFFICER | OLMA Olema Oncology, Inc. | Sale | 320 | $9.39 | $3,005 Sale | Form 4 ↗ |
| Dec 11, 2024 | Naseem Zojwalla CHIEF MEDICAL OFFICER | OLMA Olema Oncology, Inc. | Sale | 14,202 | $8.66 | $123.0K Sale | Form 4 ↗ |
| Dec 11, 2024 | Shane William Charles Kovacs CH. OPERATING & FINANCIAL OFF. | OLMA Olema Oncology, Inc. | Sale | 406 | $9.39 | $3,812 Sale | Form 4 ↗ |
| Dec 11, 2024 | Shane William Charles Kovacs CH. OPERATING & FINANCIAL OFF. | OLMA Olema Oncology, Inc. | Sale | 17,950 | $8.66 | $155.4K Sale | Form 4 ↗ |
| Dec 11, 2024 | Sean Bohen PRESIDENT AND CEO, Director | OLMA Olema Oncology, Inc. | Sale | 1,267 | $9.39 | $11.9K Sale | Form 4 ↗ |
| Dec 11, 2024 | Sean Bohen PRESIDENT AND CEO, Director | OLMA Olema Oncology, Inc. | Sale | 55,907 | $8.66 | $484.2K Sale | Form 4 ↗ |
| Dec 10, 2024 | Cyrus Harmon Director | OLMA Olema Oncology, Inc. | Sale | 8,256 | $9.37 | $77.4K Sale | Form 4 ↗ |
| Dec 10, 2024 | David C. Myles CH. DISCOV. & NON-CLIN DEV OFF | OLMA Olema Oncology, Inc. | Sale | 12,452 | $9.38 | $116.8K Sale | Form 4 ↗ |
| Dec 10, 2024 | Naseem Zojwalla CHIEF MEDICAL OFFICER | OLMA Olema Oncology, Inc. | Sale | 13,283 | $9.37 | $124.5K Sale | Form 4 ↗ |
| Dec 10, 2024 | Shane William Charles Kovacs CH. OPERATING & FINANCIAL OFF. | OLMA Olema Oncology, Inc. | Sale | 16,803 | $9.37 | $157.4K Sale | Form 4 ↗ |
| Dec 10, 2024 | Sean Bohen PRESIDENT AND CEO, Director | OLMA Olema Oncology, Inc. | Sale | 52,328 | $9.37 | $490.3K Sale | Form 4 ↗ |
| Jun 4, 2024 | Graham G. Walmsley Director | OLMA Olema Oncology, Inc. | Sale | 475,000 | $14.85 | $7.1M Sale | Form 4/A ↗ |
| Jun 4, 2024 | Graham G. Walmsley Director | OLMA Olema Oncology, Inc. | Sale | 700,000 | $14.85 | $10.4M Sale | Form 4/A ↗ |
49 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 5:29 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances